Positions

Overview

  • I am dual-trained in both Medical Hematology/Oncology and Clinical Pharmacology and Pharmacogenomics at the University of Chicago. My specialty training allowed me to develop expertise in clinical trial design, pharmacokinetics (PK)/pharmacodynamics (PD) analysis, drug development, and patient care. In September 2015, I joined the faculty at the University of Alabama at Birmingham as an Assistant Professor of Medicine. My focus remains in highly aggressive women’s malignancies (i.e. triple-negative and HER2+ breast cancer as well as high-grade serous ovarian cancer) and early-phase clinical trial design. In this role, I serve as a clinician-scientist helping laboratory-based scientist translate laboratory findings to the clinical setting by designing trials.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumorsClinical Cancer Research.  27:4511-4520. 2021
    2021 Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)European journal of cancer.  153:223-233. 2021
    2021 Disparities in Breast Cancer Associated With African American Identity.American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  41:e29-e46. 2021
    2021 Breast cancer, version 4.2021 featured updates to the NCCN guidelines 2021
    2020 Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical TrialJAMA Oncology.  6:1355-1362. 2020
    2020 Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Oncology.  6:676-684. 2020
    2020 Breast cancer, version 3.2020 2020
    2020 MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trialJournal of Clinical Oncology.  38:1059-1069. 2020
    2019 Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology.  5:1141-1149. 2019
    2018 Future Developments in Neoadjuvant Therapy for Triple-Negative Breast CancerSurgical Clinics of North America.  98:773-785. 2018
    2017 MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancerBreast Cancer Research.  19. 2017
    2016 A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerSpringerPlus.  5. 2016
    2015 Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinomaGynecologic Oncology.  138:656-662. 2015

    Chapter

    Year Title Altmetric
    2014 Chemotherapy and/or targeted therapies for advanced endometrial cancer: Time to rethink?.  59-68. 2014

    Research Overview

  • Breast Cancer
    Ovarian Cancer
    Developmental Therapeutics
    Translational Research
  • Principal Investigator On

  • A New Paradigm: Using PARP Inhibitors to Treat HER2+ Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • PARP Inhibitors: A Novel Mechanism to Overcome Resistance in Aggressive HER2+Breast Cancers  awarded by V FOUNDATION FOR CANCER RESEARCH
  • Private Grant  awarded by CASCADIAN THERAPEUTICS
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TESARO, INC.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM
  • TBCRC 037 UAB 1644:A Trial of Endocrine Response In Women with Invasive Lobular Breast Cancer.  awarded by University of Pittsburgh The
  • TBCRC 040: Pathologic Response Evaluation & Detection In Circulating Tumor DNA (PREDiCT DNA)  awarded by Johns Hopkins University
  • TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer  awarded by Johns Hopkins University
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer  awarded by Johns Hopkins University
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE
  • UAB 17127-A Phase 1b Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2–/FGFR-Amplified Metastatic Breast Cancer (MBC)  awarded by VANDERBILT UNIVERSITY
  • UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.  awarded by University of Chicago ^
  • UAB 18106:OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy  awarded by Georgetown University
  • Investigator On

  • A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR” Study  awarded by Johns Hopkins University
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE R20-080  awarded by ECOG-ACRIN CANCER RESEARCH GROUP
  • Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women  awarded by National Cancer Institute/NIH/DHHS
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • Personalizing Immunotherapy in HER2+ Breast Cancer through Quantitative Imaging  awarded by National Cancer Institute/NIH/DHHS
  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison
  • Precision Metabolic Therapy of p53 Mutant Triple Negative Breast Cancers  awarded by National Cancer Institute/NIH/DHHS
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by TESARO, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDICINE
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERSANA THERAPEUTICS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by SERMONIX PHARMACEUTICALS INC
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by ELEVATION ONCOLOGY INC.
  • Private Grant  awarded by DAIICHI SANKYO, INC.
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM
  • Private Grant  awarded by LILLY USA, LLC
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University
  • Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer  awarded by National Cancer Institute/NIH/DHHS
  • TBCRC -AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer  awarded by Johns Hopkins University
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University
  • TBCRC 033 UAB 1568: A Randomized Phase II study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage 1 HER2-Positive Breast Cancer (ATEMPT Trial)  awarded by Dana-Farber Cancer Institute
  • TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)  awarded by Johns Hopkins University
  • TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib  awarded by Lineberger Comprehensive Care Center
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University
  • TBCRC 042 UAB 1905: A Randomized, Phase II, Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions  awarded by Johns Hopkins University
  • TBCRC 048 UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE
  • UAB 1428 – A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HOG Trial)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • UAB 1430 - A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 inhibitor, in Combination with Anastrozole in Women with Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer  awarded by Washington University
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION
  • Utilizing microRNA-146a to Block Triple-Negative Breast Cancer Cell Colonization  awarded by National Cancer Institute/NIH/DHHS
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University
  • XUAB 1769: Phase lb 9cUAB30 In Early Stage Breast Cancer to Evaluate Biologic Effect (Cost Reimbursable)  awarded by University of Wisconsin-Madison
  • XUAB 2023-IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated with NeoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT Study  awarded by Johns Hopkins University
  • XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer (R20-146)  awarded by ECOG-ACRIN CANCER RESEARCH GROUP
  • Education And Training

  • Tulane University, Internship
  • Baptist Health System, Residency
  • University of Chicago, Postdoctoral Fellowship
  • University of Chicago, Postdoctoral Fellowship
  • Doctor of Medicine, University of South Alabama 2008
  • Bachelor of Science or Mathematics in Biomedical Sciences, Auburn University 2004
  • Full Name

  • Erica Stringer-Reasor